• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Transporting Treatment: An Examination of Tubing Technologies

    Outward Appearance: Reviewing Surface Treatment Options

    Face to (Virtual) Face: Telemedicine Now and Post-Pandemic

    Voices for Medtech: AdvaMed and MDMA Leaders Share Thoughts

    Digitize Your QMS via an Enterprise Cloud Platform
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    FDA Grants 510(k) Clearance to LivaNova’s B-Capta

    Gynesonics Appoints Susan Stimson to Its Board of Directors

    Piezo Motion Debuts Piezoelectric Micro-Dosing Pump

    Riva Health Raises $15.5 Million for Breakthrough Mobile Cardiology Technology

    Abbott Begins Shipping Rapid COVID Self-Tests
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Transporting Treatment: An Examination of Tubing Technologies

    Outward Appearance: Reviewing Surface Treatment Options

    Face to (Virtual) Face: Telemedicine Now and Post-Pandemic

    Voices for Medtech: AdvaMed and MDMA Leaders Share Thoughts

    Digitize Your QMS via an Enterprise Cloud Platform
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Home Is Where the Heart (Valve) Is

    CGM: Digital Health Meets a Very Large Opportunity

    Biomechanical Engineer, Heal Thyself

    Optimizing MIM in Medical Device Manufacturing

    PPE and Diagnostics: Sourcing Domestically and Speeding Time to Market
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Trademark Plastics Inc.

    Concise Engineering

    FUTEK Advanced Sensor Technology Inc.

    Forefront Medical Technology

    Unicep
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    EMS' Engineering Resources Increasingly in Demand

    Fiber Optics Introducing New Cleanliness Requirements for Medical Electronics

    EMS Providers Valued for Product Customization, Medical Certification Expertise

    Three Future Trends and Opportunities in Quality Assurance

    Adopting a Data-Driven Quality Model
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Spectrum Plastics Group

    Medbio LLC

    PTI Engineered Plastics Inc.

    Concise Engineering

    maxon
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    Deep Brain Stimulation May Address Chronic Depression in Some Patients

    New dataset highlights the largest prospective study in DBS for chronic, treatment-resistant depression.

    Deep Brain Stimulation May Address Chronic Depression in Some Patients
    Currently, DBS is not currently indicated for depression and Abbott's Libra system is FDA-approved only to offer DBS for essential tremor and Parkinson's disease. Image courtesy of Abbott.
    Related CONTENT
    • Encora's Tremor Reducing Wristband Gains Breakthrough Status
    • Abbott Releases NeuroSphere Virtual Clinic for Remote Neuromodulation Care
    • Boston Scientific's Vercise Genus DBS Earns FDA Approval
    • Abbott's FreeStyle Libre 3 Receives CE Mark
    • Abbott’s MitraClip G4 Receives CE Mark
    Abbott Laboratories10.12.17
    New data published in The Lancet: Psychiatry has found that deep brain stimulation (DBS) may offer some patients an option for managing their chronic, treatment-resistant depression. The data, which stems from the Abbott-sponsored BROADEN Study, also provides safety and feasibility results of DBS therapy as a treatment for these patients and the authors concluded that after 24 months of stimulation, nearly half of all DBS patients responded to the therapy. Of these patients, 26 percent of patients experienced remission of their depression; a remission rate that steadily grew over time.
     
    While the BROADEN study initially found no statistically significant difference in efficacy between the stimulation group and the control group after six and 12 months, after the initial 12-month study, 77 of 90 participants entered into a four-year follow-up study. Within that follow-up study, the authors found that patients receiving DBS therapy saw response and remission rates of 29 percent and 14 percent at 12 months, 53 percent and 18 percent at 18 months, and 49 percent and 26 percent at 24 months, respectively. Currently, DBS is not currently indicated for depression and Abbott is FDA-approved only to offer DBS for essential tremor and Parkinson's disease.
     
    "Innovation within the field of neuroscience takes time and is filled with opportunities to learn, adapt and learn again. This study is a strong example of how our therapies can contribute to the innovation taking place within the broad field of neuroscience," said Allen Burton, M.D. medical director within Abbott's Neuromodulation Division. "We applaud the researchers who led this study and look forward to future advancements to support the care of people suffering from chronic, treatment-resistant depression."
     
    Depression affects more than 21 million adults in the U.S., according to the National Institute of Mental Health. Nearly 4 million people live with severe depression that doesn’t respond to traditional treatment or multiple treatment attempts.
     
    "While I am disappointed by the initial results, I’m encouraged by the long-term outcomes seen in this trial, which are consistent with previous and ongoing experience with DBS outside of this clinical trial," said Helen Mayberg, M.D., professor of psychiatry, neurology and radiology at Emory University in Atlanta, Ga. "There are refinements to optimize DBS delivery that may prove useful to understand these findings and move the therapy forward. For example, we now know that implantation method and directionality matter for optimal patient outcomes. We look forward to seeing what new innovations, such as use of advanced imaging to guide the implantation and use of directional leads, can do in the future."
     
    Assessing a New Approach to Depression Treatment
    Clinical research has often implicated activity within an area of the brain known as “Brodmann Area 25” as compounding treatment-resistant depression. Researchers have pointed to DBS as a new option for patients because modern systems can precisely target stimulation to this area and deliver remission to patients who had not responded to prior therapy attempts.
     
    Abbott originally launched the randomized controlled BROADEN study in 2008 to assess DBS therapy in patients with chronic, treatment-resistant depression. The study, which utilized the investigational Abbott Libra deep brain stimulation system, built upon a pilot study that showed meaningful reductions in depression in patients receiving DBS therapy and on the groundbreaking work of Dr. Mayberg and colleagues that supported the application of DBS therapy in patients with treatment-resistant depression. When the BROADEN study was discontinued, patients were then monitored in a follow-up study.
     
    The BROADEN study enrolled 128 patients and implanted 90 between the ages of 21 and 70 years of age at 13 centers who had been diagnosed with major depressive disorder. Patients must have tried at least four treatments for their depression without a meaningful treatment response. Patients should talk to their physician about the benefits and risks of any DBS therapy option and should consider this data as investigational in nature and not indicative. 
    Related Searches
    • forward
    • led
    • institute
    • fda
    Related Knowledge Center
    • Neurological
    Suggested For You
    Encora Encora's Tremor Reducing Wristband Gains Breakthrough Status
    Abbott Releases NeuroSphere Virtual Clinic for Remote Neuromodulation Care Abbott Releases NeuroSphere Virtual Clinic for Remote Neuromodulation Care
    Boston Scientific Boston Scientific's Vercise Genus DBS Earns FDA Approval
    Abbott Abbott's FreeStyle Libre 3 Receives CE Mark
    Abbott’s MitraClip G4 Receives CE Mark Abbott’s MitraClip G4 Receives CE Mark
    Abbott Introduces World Abbott Introduces World's First Glucose Biosensor Designed for Athletes
    Boston Scientific Launches Vercise Genus DBS System In Europe Boston Scientific Launches Vercise Genus DBS System In Europe
    Abbott Begins Study for New Esprit BTK Fully Resorbable Stent Abbott Begins Study for New Esprit BTK Fully Resorbable Stent
    Feds to Buy $760M of Abbott Feds to Buy $760M of Abbott's $5, 15-Minute COVID-19 Test
    FDA Grants EUA to Abbott FDA Grants EUA to Abbott's $5, 15-Minute, COVID Antigen Test
    Neurolief Neurolief's Relivion DP Headset for Major Depression Earns Breakthrough Status
    Abbott Begins Study Evaluating New Device to Treat Recurrent AFib Abbott Begins Study Evaluating New Device to Treat Recurrent AFib
    Abbott Vascular Executive Assumes Chief Medical Officer Role at Abiomed Abbott Vascular Executive Assumes Chief Medical Officer Role at Abiomed
    Former Abbott Labs Exec is Named COO at Inspire Medical Systems Former Abbott Labs Exec is Named COO at Inspire Medical Systems
    FDA OKs Abbott’s iOS-Compatible Therapy Management App FDA OKs Abbott’s iOS-Compatible Therapy Management App

    Related Breaking News

    • Neurological
      ZOLL Buys Sleep Apnea Device Maker Respicardia

      ZOLL Buys Sleep Apnea Device Maker Respicardia

      Respicardia's remedē system, an implantable neurostimulator, treats central sleep apnea.
      Sam Brusco, Associate Editor 04.12.21

    • Neurological
      Encora

      Encora's Tremor Reducing Wristband Gains Breakthrough Status

      Indicated to provide temporary hand tremor relief in adult essential tremor or Parkinson's patients.
      Sam Brusco, Associate Editor 03.31.21

    • Neurological | Patient Monitoring
      FDA OKs Brain Scientific

      FDA OKs Brain Scientific's Next-Gen NeuroCap EEG Headset

      NeuroCap's advanced EEG electrode array obtains rapid EEGs in routine clinical and research settings.
      Sam Brusco, Associate Editor 03.10.21


    • Neurological
      Medtronic Receives FDA Approval for Expanded MRI Labeling

      Medtronic Receives FDA Approval for Expanded MRI Labeling

      Updated MRI Guidelines allow for a wider range of MRI scan parameters and shorter wait time between MRI scans.
      Charles Sternberg, Assistant Editor 02.18.21

    • Neurological
      FDA OKs electroCore

      FDA OKs electroCore's gammaCore nVNS for Adolescent Migraine

      It’s now cleared for most forms of primary headache.
      Sam Brusco, Associate Editor 02.16.21

    • Neurological
      FDA Approves Axonics

      FDA Approves Axonics' 3rd-Gen Implantable Neurostimulator

      Upgrades its embedded software and the patient remote control’s functionality.
      Sam Brusco, Associate Editor 02.16.21


    • Cardiovascular | Neurological
      Cerus Endovascular

      Cerus Endovascular's Contour Neurovascular System Gains Breakthrough Status

      Indicated for the treatment of intracranial aneurysms.
      Sam Brusco, Associate Editor 02.12.21

    • Neurological
      Nēsos Earbud Receives Validation for Treatment of Rheumatoid Arthritis

      Nēsos Earbud Receives Validation for Treatment of Rheumatoid Arthritis

      New study shows promising efficacy and safety profile for novel ‘e-mmunotherapy’ approach to disease treatment.
      Charles Sternberg, Assistant Editor 02.02.21

    • Neurological
      Boston Scientific

      Boston Scientific's Vercise Genus DBS Earns FDA Approval

      Fourth-generation DBS portfolio features full-body MR conditional devices.
      Sam Brusco, Associate Editor 01.22.21


    • Neurological
      Cognito Therapeutics’ Lead Product Receives FDA Breakthrough Device Designation

      Cognito Therapeutics’ Lead Product Receives FDA Breakthrough Device Designation

      Next-generation digital therapeutic is designed for the treatment of Alzheimer’s disease.
      Business Wire 01.14.21

    • Neurological
      Medtronic Begins Adaptive Deep Brain Stimulation Trial for Parkinson

      Medtronic Begins Adaptive Deep Brain Stimulation Trial for Parkinson's

      First-of-its-kind study tests automated therapy that responds to brain signals in Parkinson's patients.
      PR Newswire 01.14.21

    • Neurological | Surgical
      FDA OKs ClearMind Biomedical

      FDA OKs ClearMind Biomedical's Axonpen Neuroendoscope

      Requires only a narrow channel of 6.5mm through the skull for insertion into the brain.
      PR Newswire 01.12.21


    • Diagnostics | Neurological
      FDA OKs Abbott

      FDA OKs Abbott's First-of-Its-Kind Rapid, Handheld TBI Test

      Produces a result within 15 minutes after a plasma sample is inserted.
      Abbott Laboratories 01.11.21

    • Neurological
      BioSerenity Achieves FDA Clearance for Wearable Device System

      BioSerenity Achieves FDA Clearance for Wearable Device System

      Neuronaute EEG System and IceCap bring comprehensive remote electroencephalography monitoring services to people living with neurological disorders.
      PRNewswire 01.07.21

    • Cardiovascular | Neurological | Surgical
      FDA OKs Rapid Medical

      FDA OKs Rapid Medical's Steerable Neurovascular Guidewire

      Provides efficient access in difficult neuro and peripheral vascular procedures.
      Business Wire 01.04.21


    Trending
    • Portable, Home-Use Device Quickly Measures Inflammation Levels
    • Survey: Remote Patient Monitoring To Match Or Surpass In-Patient Within Five Years
    • Harnessing Critical Health Data With Wearable Technology
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    • Device Designed To Permanently Replace Failing Human Hearts
    Breaking News
    • FDA Grants 510(k) Clearance to LivaNova’s B-Capta
    • Gynesonics Appoints Susan Stimson to Its Board of Directors
    • Piezo Motion Debuts Piezoelectric Micro-Dosing Pump
    • Riva Health Raises $15.5 Million for Breakthrough Mobile Cardiology Technology
    • Abbott Begins Shipping Rapid COVID Self-Tests
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Transporting Treatment: An Examination of Tubing Technologies
    • Face to (Virtual) Face: Telemedicine Now and Post-Pandemic
    • Outward Appearance: Reviewing Surface Treatment Options
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Longvida Curcumin Extract Receives ANVISA Approval in Brazil
    Curcugen Curcumin Formulation Evidenced to Attenuate Post-Exercise Inflammation
    Good Rāz Launches Taste-Free Vitamin D3 Drops
    Coatings World

    Latest Breaking News From Coatings World

    USGBC Releases Results of 2021 Green Building Community Survey
    PPG Publishes Sustainability Report
    Sherwin-Williams Launches Echelon
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA Grants 510(k) Clearance to LivaNova’s B-Capta
    Gynesonics Appoints Susan Stimson to Its Board of Directors
    Piezo Motion Debuts Piezoelectric Micro-Dosing Pump
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Evotec to Build Second Biologics Mfg. Facility in Toulouse
    Adare Pharma Names Ludger Roedder President of Adare Biome
    Johnson & Johnson 1Q Results
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Donginbi Launches Men’s Skincare Collection
    Kiehl’s Launches Pouch Refillables
    Skin Match Technology Partners with Men-Only Grooming Platforms
    Happi

    Latest Breaking News From Happi

    Robertet Appoints Reichert as Perfumer
    Kiehl’s Launches Sustainable Pouch Refillables for Hair Care, Skin Care
    New OTC Natural Hemp Pain Relief Gel Arrives at cbdMD
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    PPG releases 2020 Sustainability Report
    GAA merges with AIMCAL
    Acucote expands Insights educational program
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Glatfelter GlatClean Nominated for World of Wipes Innovation Award
    P&G’s Sales Up 5%
    Ontex Tests Industrial Scale Diaper Composting
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Spinal Elements' Lucent 3D Additive Manufactured Interbodies Earn FDA Nod
    Conformis, Paragon 28 Ink Licensing Deal
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI Appoints imec, Soitec Executives to Europe Advisory Board
    NREL Takes Novel Approach to 3D-Printed Water Power Prototypes
    Canatu Manufactures World’s Thinnest Free-standing CNB Membrane

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login